Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndr… Read More
SHELTON, CONNECTICUT — Monday, October 16, 2023 — NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal… Read More
Companion diagnostics (CDx) provides information essential for the safe and effective use of a corresponding intervention. Clinical practice is shifting to the era of precision medicine, and… Read More
· Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patien… Read More
At the outset, cancer vaccines were plagued with false starts and modest success at best. But they now represent a promising therapeutic strategy in the immunotherapy of solid tumors.
&ldq… Read More
New Delhi: Citing that the proposed fixed-dose combination (FDC) of antidiabetic drug Metformin HCl plus Glimepiride plus Lobeglitazone sulfate tablet is not approved internationally, the Su… Read More
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete… Read More
Health Canada has approved the oral GnRH receptor antagonist relugolix (Orgovyx ) for the treatment of patients with advanced prostate cancer.1
The approval is based on results from the ph… Read More